

## Adipose derived stem cells: new kids on the block

E. Meliga<sup>1,2</sup>, MD; H.J Duckers<sup>1</sup>, MD, PhD; R.J. van Geuns<sup>1</sup>, MD; E. Regar<sup>1</sup>, MD, PhD;  
P. de Jaegere<sup>1</sup>, MD, PhD; W. van der Giessen<sup>1</sup>, MD, PhD; P.W. Serruys<sup>1\*</sup>, MD, PhD

1. Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands; 2. Interventional Cardiology department, S. Giovanni Battista Hospital, University of Turin, Italy

All authors have no conflict of interest to declare.

### KEYWORDS

Cell therapy, heart failure, adipose tissue, stem cells

### Abstract

Heart failure is a major health problem and myocardial infarction (MI) is, at the present time, the main cause. Cell therapy hold great promise for use in tissue regeneration and is increasingly used in an effort to improve outcomes in cardiac disease. Recently it has been shown that adipose tissue, in addition to committed adipogenic, endothelial progenitor cells and pluripotent vascular progenitor cells, contains also multipotent cell types (adipose derived stem cells, ADSCs) that, in cell culture conditions, have extensive proliferative capacity and are able to differentiate into several lineages, mesenchymal or not.

ADSCs, similarly to MSCs, express the CD105, STRO1, CD166, CD117, CD90, CD54, CD44 and CD29 surface markers. Moreover, ADSCs are also capable of secreting a large number of growth factors, including vascular endothelial growth Factor, Granulocyte/Macrophage Colony Stimulating Factor, Stromal Derived Factor-1alpha and Hepatocyte Growing Factor.

Adipose tissue can be harvested in large amounts with minimal morbidity and, owing to the large concentration of stem cells contained in a typical harvest, therapeutic doses of ADSCs can easily be isolated in as little as an hour after liposuction, obviating the need for culture. Several studies conducted in porcine AMI models have shown a significant LV functional improvement, with no report of any potentially fatal arrhythmias. The APOLLO trial, a prospective, double blind, randomised, placebo controlled, sequential dose-escalation study conducted at the Thoraxcenter, Erasmus MC, will be the 'First-in-Man' study that will explore the safety and feasibility of ADSC transplantation in patients with acute MI.

\* Corresponding author: Thoraxcenter, Erasmus University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands.

E-mail: p.w.j.c.serruys@erasmusmc.nl

## Introduction

Despite recent developments in the treatment of coronary artery disease and the introduction of new devices and effective post PCI therapies, the loss of cardiac tissue and the resulting impairment of left ventricular function after myocardial infarction (MI) remains a main cause of heart failure, defining the need to find an effective treatment to ameliorate this major health problem and its economic consequences. The potential of cell transplantation to repair damaged myocardium is attractive and has been widely studied in both experimental and clinical conditions using various cell types<sup>1-6</sup>. The quest for the ideal cell is still ongoing, as the attributes of the ideal cell and working mechanism of cell regeneration still remain to be defined. Nonetheless, there appears to be a consensus that, among the cells effective in the treatment of heart disease, cells that are autologous, non-embryonic, do not require culturing to obtain a therapeutic dose, and can be administered during the same procedure, may be logistically easier to use and thus may have wider application in catheterisation laboratories.

The most extensively studied and characterised cells, that have been shown to have some of the above mentioned ideal properties, are mesenchymal stem cells (MSCs). MSCs are multipotent, adult stem cells, that can expand in cell culture and are able to differentiate into multiple cell phenotypes including bone, cartilage, neuronal and skeletal muscle progenitor cells, but also into vascular endothelial cells and cardiomyocytes<sup>7-13</sup>.

Many previous cell therapy trials in patients with AMI, have been using mononucleated bone marrow derived cells (BMCs)<sup>14-17</sup>, that consist of a heterogeneous cell population. A small fraction of these unfractionated BMCs are MSCs. Results of these trials showed an improvement of regional wall motion, global ejection fraction and, in some cases, a reduction of infarct size in the treated group<sup>14,16</sup>. Selected MSCs were evaluated by Chen and colleagues in 2004<sup>18</sup> in 34 patients demonstrating a significant improvement of regional wall motion, global ejection fraction, reduction of infarct size, but also reduction of left ventricular end diastolic volume (LVEDV) in the treated group, confirming the encouraging results obtained from previous preliminary animal studies<sup>19-21</sup>. So far, these cells have been harvested from bone marrow, however, limitations of this cell source are: 1) the number of MSCs in bone marrow is rather low; MSCs in fact represent < 0.01% of all nucleated bone marrow cells in healthy volunteers (approximately 1 in 25,000 to 1 in 100,000)<sup>22,23</sup>; 2) donor site morbidity limits the amount of marrow that can be obtained (generally limited to no more than 40 ml)<sup>24,25</sup> and consequently 3) the long time required to obtain therapeutic cell doses by *ex vivo* cell expansion renders treatment in the acute phase of myocardial infarction impractical.

Recently it has been shown that adipose tissue, in addition to committed adipogenic, endothelial progenitor cells and pluripotent vascular progenitor cells, contains also multipotent cell types<sup>26,27</sup>. This finding has generated major interest because, in contrast to bone marrow, adipose tissue can be easily and safely harvested in large quantities and with minimal morbidity regardless of the condition of the patient, making it an appealing source for cell therapy.

## Cell characteristics

Adipose tissue, differently from most tissues, has a remarkable plasticity during life. Although increases in volume can be partially obtained by increasing the amount of lipids stored in the already existing adipocytes (cellular hypertrophy), large increases in volume are usually associated with an increase in adipocyte count (cellular hyperplasia) accompanied by a concomitant expansion and remodelling of the microvasculature supplying these cells<sup>28</sup>.

The hyperplastic process of the adipose tissue and supporting vascular bed is mediated by a cell population present within the stromal vascular fraction of adipose tissue generally referred to as adipose derived stem cells (ADSCs). These cells, previously supposed to be mono-potent adipocyte progenitor cells, called pre-adipocytes, have actually been demonstrated to have an impressive developmental plasticity<sup>27,29</sup> including the ability to undergo multi-lineage differentiation and self-renewal<sup>26,30-32</sup> (Figure 1).




Figure 1. ADSCs actions and effects; ADSCs have an impressive developmental plasticity including the ability to undergo multi-lineage differentiation, to act by paracrine effects and to display an immuno-privileged behaviour.

ADSCs are a cell population with properties that are very similar, though not identical, to those of marrow derived MSCs<sup>33-36</sup>. These cells have extensive proliferative capacity and are able to differentiate in cell culture conditions into osteogenic, chondrogenic, myogenic lineages<sup>7-13,37</sup> and, more recently, into a neurogenic phenotype<sup>9,38</sup>.

In culture, these cells express surface markers that are similar to those expressed by MSCs (Table 1): both cell types express CD105, STRO1 and CD166 (multi-lineage differentiation markers)<sup>39-42</sup>, CD117 (stem cell factor receptor), CD90, CD54 (ICAM-1), CD44 and CD29 (beta-1 integrin)<sup>13,43,44</sup>, whereas both cell types do not express the endothelial markers CD31, CD34 and the haematopoietic marker CD45<sup>35,39</sup> (Figure 2).

Recent studies showed that freshly isolated human ADSCs from subcutaneous adipose tissue tested positive for the aforementioned

**Table 1. Cell surface characteristics of adipose derived stem cells and mesenchymal stem cells.**

Cell-surface marker	ADSCs	MSCs
CD29	+	+
CD44	+	+
CD54	+	+
CD90	+	+
CD105	+	+
CD166	+	+
STRO-1	+	+
CD31	-	-
CD34	-	-
CD45	-	-
CD49D	+	-
CD106	-	+




Figure 2. Representative sample of freshly isolated ADSCs. CD45<sup>+</sup>, CD34<sup>bright</sup> and CD31<sup>bright</sup> cells correspond to approximately 38.6, 56.5 and 6.8% of total cells. Cells were analysed using FACSDiva software (Picture from Cytori Therapeutics).

markers of haematopoietic and endothelial lineage. Flow cytometric characterisation of human ADSCs in culture revealed that the percentage of cells positive for CD34 expression decreased markedly after 1 week of culture<sup>45</sup> suggesting that the adhesion of ADSCs to plastic leads to a selection similar to that seen with MSCs, increasing the proportion of a unique population of cells with immature characteristics<sup>46</sup>.

One of the most interesting differences in surface markers between MSCs and ADSCs is a reciprocal expression pattern of the very-late-activation antigen 4 or VLA-4 (CD49d/CD29) and its cognate receptor vascular cell-adhesion molecule 1 or VCAM-1 (CD106). ADSCs express VLA-4 but not VCAM-1 in the majority of donors, while MSCs usually express CD106, a component of VCAM-1, and not VLA-4<sup>35</sup>.

The consequences of these properties are not clear yet and needs further investigation, but this observation is fascinating since both these molecules play an important role in haematopoietic stem cell homing and mobilisation from the bone marrow<sup>47,48</sup>.

MSCs but also ADSCs are known to secrete a large number of angiogenesis-related cytokines<sup>45</sup>. In ADSCs in standard cultures, high levels of Hepatocyte Growth Factor (HGF), Vascular Endothelial Growth Factor (VEGF), Placental Growth Factor (PGF), Transforming Growth Factor- $\beta$  (TGF- $\beta$ ), Fibroblast Growth Factor (FGF), Granulocyte/Macrophage Colony Stimulating Factor (GM-CSF), Monocyte Chemotactic Protein-1 (MCP-1) and Stromal Derived Factor-1 $\alpha$  (SDF-1 $\alpha$ ) were observed, suggesting an

active role of ADSCs in neovascularisation<sup>45,49</sup>. ADSCs and MSCs both possess the capability to suppress lymphocyte reaction in a dose-dependent and time dependent fashion; such immunosuppression probably occurs via the production of cytokines (including IL-4, IL-10, and TGF- $\beta$ ) responsible for the inhibition of lymphocyte proliferation<sup>50,51</sup>.

Clonally-derived, multipotent cells from adipose tissue display furthermore an immuno-privileged behaviour<sup>33</sup>. Less than 1% of ADSCs in fact express the cell surface MHC class-I whereas class-II is almost absent<sup>52</sup>. Therefore ADSC are poorly recognised by T-lymphocytes, as suggested by the absence of infiltration by myeloid CD3 positive cells. When injected into immuno-competent X-linked muscular dystrophy (mdx) mouse muscles, ADSCs were seen to differentiate into functional muscle cells, integrated by fusing with host cells and were not rejected up to 6 months after transplantation<sup>33</sup>. This, together with the easy availability and the small amount of tissue needed for their isolation, suggests that, ADSCs might even have potential as immuno-privileged universal donor cells with the capacity to be used not only for autologous but also for allogeneic transplantation.

## Harvest and expansion

Subcutaneous adipose tissue can be safely and quickly harvested in large quantities in several regions of the body, using conventional liposuction. A typical harvest out of 100-200 ml of human adipose tissue would yield about  $50 \times 10^6$  nucleated cells. During a regular liposuction procedure, it is not uncommon for plastic surgeons to remove in excess of 2,000 mL of fat. The samples are then enzymatically digested, filtered and centrifuged to separate the non-buoyant stromal cells from the buoyant adipocytes<sup>46,53,54</sup>. The non-buoyant fraction can yield in excess of  $1 \times 10^6$  stem cells (from 100 cc of fat tissue), about 45 fold more than a typical harvest of bone marrow aspiration (of 40 ml) which typically contains  $2.5 \times 10^4$  MSCs in a mature adult<sup>25,55</sup>. If necessary, the ADSC containing fraction can be cultured with different media (e.g. DMEM-F12; EGM-2-MV,  $\alpha$ -MEM etc.) and supplemented with different percentages of serum and growth factors (e.g. VEGF, Insulin Like Growth Factor, bF Growth Factor etc.) to stimulate differentiation into dedicated lineages and expansion. (Figure 3) Owing to the great concen-




Figure 3. ADSCs form cords in an in vitro tubule formation assay. ADSCs cultured for 1 week form cords in EGM-2. Immunofluorescence was used to detect CD31 (red) and von Willibrand factor (vWF, green). Cell nuclei were detected by DAPI (blue). Adult dermal fibroblasts were used as a control (bottom row).

tration of ADSCs normally present in the adipose tissue harvest, it is also possible to instantaneously obtain therapeutic cell doses, with no need for further expansion in culture<sup>56</sup>. In contrast to BM-derived MSCs, therapeutic doses of ADSCs can easily be isolated in as little as an hour after liposuction<sup>45,46</sup>. This not only obviates the need for culture, but also avoids cell alterations associated with culturing.

### Differentiation capabilities of ADSCs

Numerous studies have demonstrated that ADSCs, similarly to MSCs, have the capability to undergo differentiation into several cell types along both mesenchymal (fat, bone, cartilage muscle, nerve) and non-mesenchymal lineages (blood vessel)<sup>7-13,38,57</sup>, demonstrating that adipose tissue actually contains pluripotent cells.

In particular, as far as muscle differentiation is concerned, evidence showed that ADSCs have the ability to differentiate into contractile cells with both striated muscle cells or cardiomyocyte features<sup>53,58-62</sup>.

### In vitro studies of ADSC differentiation

After two weeks of culture in RPMI medium, 20% to 30% of ADSCs increased in size, changed shape and began to beat spontaneously when observed under a phase contrast microscope by three weeks, as observed by Rangappa et al in 2003<sup>57</sup>. Likewise, after three weeks of exposure to rat cardiomyocytes conditioned DMEM medium, ADSCs expressed cardiomyocyte markers including sarcomeric alpha-actin, desmin, and cardiac troponin I, as well as the gap junction protein Connexin-43 (Cx-43) and started to beat spontaneously, as observed by Gaustad et al in 2004<sup>58</sup>.

In 2005, Planat-Benard et al<sup>53</sup> obtained similar results by plating fresh ADSCs in a semi-solid culture. After three weeks of culture, ADSCs morphologically developed into ventricle-like, atrial-like and pacemaker-like cells, displaying tight inter-cellular connections (evidenced by Cx-43) and spontaneous, as well as triggered action potentials with beating. Moreover, these differentiated cells expressed the cardiac-specific transcription factors Nkx2.5, GATA-4, and MEF-2C, the structural cardiac proteins  $\beta$ -myosin heavy chain (MHC), myosin light chain-2 ventricular (MLC-2v), myosin light chain-2 atrial (MLC-2a) as well as the atrial natriuretic peptide (ANP), whereas the skeletal marker MyoD and smooth muscle actin were not expressed.

### In vivo studies of ADSC differentiation

Several groups have so far reported data about the safety and efficacy of ADSCs to regenerate damaged myocardium in both small (rats) and large animals (pigs).

Delivery of ADSCs by intracoronary infusion to pigs two days after an acute MI through a LAD balloon occlusion (Watanabe et al, 2004) resulted in a 3% absolute increase in LVEF while the untreated pigs showed a 9% decline at 6-month FU ( $P < 0.01$ )<sup>59</sup>. Likewise, intracoronary infusion of either ADSCs or MSCs in an acute MI pig model (Valina et al, 2004) resulted in a 11.4% improvement of absolute LVEF after 4 weeks, compared to only 2% improvement in the non-treated group ( $P < 0.003$ )<sup>60</sup>.

Strem and colleagues<sup>61</sup> in 2005 used intraventricular injections to deliver freshly isolated allogeneic ADSCs from Rosa 26 mice (expressing the beta-galactosidase transgene) into syngeneic recip-

ient mice, following myocardial cryoinjury. Beta-galactosidase positive cells were found in treated mice together with the expression of MHC, Nkx2.5 and with troponin I at 14 days post transplantation, suggesting that ADSCs have the ability to engraft injured myocardium and express specific cardiomyocyte markers *in vivo*.

Freshly isolated ADSCs given immediately after reperfusion in a porcine AMI model (Alt et al) resulted in a 8% LVEF increase compared to controls at 8-week FU ( $p = 0.023$ )<sup>62</sup>.

Interestingly, concordant with the functional improvement, wall thickness and capillary density were both significantly increased in the border infarct areas of the treated group, compared to the control group<sup>63</sup>.

In a study recently published by Miyahara and colleagues<sup>54</sup>, ADSCs were transplanted directly onto infarcted murine hearts as a monolayered cell sheet. After transplantation, the engrafted sheet gradually grew to form a thick stratum that included newly formed vessels, undifferentiated cells and cardiomyocytes. Autologous transplantation of ADSC sheets, resulted in a decreased LVEDP, improved maximum and minimum dP/dt, increased diastolic wall thickness, increased left ventricular fractional shortening and decreased diastolic wall stress, as compared to dermal fibroblast sheets taken as a control.

### Human studies of ADSC differentiation

ADSCs have been used successfully in a variety of indications in humans, including the treatment of Crohn's disease fistulas<sup>64,65</sup>, osteogenesis imperfecta<sup>66</sup> and for breast augmentation and reconstruction after partial mastectomy<sup>67</sup>. So far, ADSCs have not been used to treat patients with MI or ischaemic heart disease. The APOLLO trial will be the 'First-in-Man' study that will explore the safety and feasibility of ADSC transplantation in patients with acute MI. This study is a prospective, double blind, randomised, placebo-controlled, sequential dose-escalation, study that will enrol up to 48 patients with acute MI at the Thoraxcenter, Erasmus MC, Rotterdam.

Eligible patients will be enrolled following primary PCI and will undergo liposuction and isolation of the adipose derived regenerative cells fraction (ADRCs) using the Celution™ system (Figure 4). ADRCs will then be injected within 24 hours from the primary PCI into the culprit coronary artery.

Main safety endpoints will include: major adverse cardiac or cerebral event (MACCE) rates, serious adverse events (SAEs)/adverse events (AEs) rates and a composite clinical endpoint of death, MI,



Figure 4. The Celution™ system, a fully automated device for the isolation of adipose derived and adipose regenerative stem cells.

stroke and re-hospitalisation for heart failure. Main feasibility end-points are: absolute LVEF and changes in LVEF from baseline to six months; MI size; regional wall thickness and thickening in all segments; LV– end systolic volume (LV-ESV); LV– end diastolic volume (LV-EDV); and change in perfusion defect after revascularisation to six months as measured by contrast enhanced MRI, echocardiography and scintigraphy.

Patients will be followed for 36 months and will undergo imaging studies (2D/3D echocardiography, LV angiography, MRI, SPECT), functional evaluation (Left Ventricular Pressure-Volume Relationship), clinical evaluations and laboratory testing at six, 12 and 18 months.

### Side effects, adverse events and potential hurdles

One of the biggest issues related to cell therapy is the potential arrhythmogenicity of the transplanted cells. Previous reports conducted using BMCs and skeletal myoblasts showed an increased incidence of arrhythmic events in the treated groups that often led to AICD implantation<sup>68</sup>.

Though limited safety data are available to date, *in vivo* preliminary animal studies have not reported an increase in any potentially fatal arrhythmias.

Loop recorder monitoring in pigs treated with ADRCs<sup>69</sup> did not show an increase in arrhythmic events throughout the eight week follow-up period (one death in the control and ADRC group within the first week after MI). No sustained arrhythmias (e.g. bradycardia lower than 45/min or tachycardia above 165/min) were recorded in surviving animals. Moreover, at the end of the study period, programmed right ventricular stimulation failed to show an increase in susceptibility for arrhythmias by ADRC treatment. On the contrary, a significantly longer cycle length could be seen in the ADRC group at the beginning of an induced arrhythmia. This finding implies rather a reduction in the overall inducibility of malignant arrhythmias than an increase in susceptibility.

Issues associated with tissue harvest in patients with a recent AMI under high doses of anticoagulants, GP IIb-IIIa inhibitors and Aspirin are a potential concern, owing to the highly developed vascularisation of adipose tissue and the consequent bleeding risk. However, only a relatively small amount of tissue is required to obtain an effective cell dose, and haemostasis at the site of liposuction can easily be achieved by local pressure.

### Conclusions

Human adipose tissue is a unique source of multi-potent stem cells that have the ability to differentiate into vascular and cardiomyocytes lineages, secrete several factors with angiogenic and anti-apoptotic effects and demonstrate stem cell-like extensive self-renewal. Moreover, ADSCs/ADRCs, unlike bone marrow-derived MSCs, can be easily and safely obtained in large numbers, without the necessity to culture.

ADRCs have been already used in humans in different clinical settings with excellent results and few side effects. Preclinical studies conducted in animal AMI models showed encouraging results and displayed their *in vivo* capability to differentiate into cardiac muscle

cells as well as to excrete different growth factors with important pro-angiogenic effects that led to a significant improvement of ejection fraction and wall thickness.

The results of the APOLLO trial will provide an understanding of the real safety and efficacy of these cells in AMI patients, giving new insights on their possible future role in the treatment of cardiovascular disease.

### References

1. Siminiak T, Kurpisz M. Myocardial replacement therapy. *Circulation*. 2003;108(10):1167-71.
2. Dimmeler S, Zeiher AM. Wanted! The best cell for cardiac regeneration. *J Am Coll Cardiol*. 2004;44(2):464-6.
3. Dimmeler S, Zeiher AM, Schneider MD. Unchain my heart: the scientific foundations of cardiac repair. *J Clin Invest*. 2005;115(3):572-83.
4. Laflamme MA, Murry CE. Regenerating the heart. *Nat Biotechnol*. 2005;23(7):845-56.
5. Edelberg JM, Xaymardan M, Rafii S, Hong MK. Adult cardiac stem cells—where do we go from here? *Sci Aging Knowledge Environ*. 2003;2003(26):PE17.
6. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. *Nat Med*. 2003;9(6):702-12.
7. Halvorsen YD, Franklin D, Bond AL, Hitt DC, Auchter C, Boskey AL, Paschalis EP, Wilkison WO, Gimble JM. Extracellular matrix mineralization and osteoblast gene expression by human adipose tissue-derived stromal cells. *Tissue Eng*. 2001;7(6):729-41.
8. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M and others. Pluripotency of mesenchymal stem cells derived from adult marrow. *Nature*. 2002;418(6893):41-9.
9. Safford KM, Hicok KC, Safford SD, Halvorsen YD, Wilkison WO, Gimble JM, Rice HE. Neurogenic differentiation of murine and human adipose-derived stromal cells. *Biochem Biophys Res Commun*. 2002;294(2):371-9.
10. Nagaya N, Kangawa K, Itoh T, Iwase T, Murakami S, Miyahara Y, Fujii T, Uematsu M, Ohgushi H, Yamagishi M and others. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. *Circulation*. 2005;112(8):1128-35.
11. Yang L, Zheng J, Liu X, Hui G, Fei J, Guo L. [Adipose tissue-derived stromal cells differentiate into neuron-like cells]. *Sichuan Da Xue Xue Bao Yi Xue Ban*. 2003;34(3):381-4.
12. Xu Y, Malladi P, Wagner DR, Longaker MT. Adipose-derived mesenchymal cells as a potential cell source for skeletal regeneration. *Curr Opin Mol Ther*. 2005;7(4):300-5.
13. Fraser JK, Wulur I, Alfonso Z, Hedrick MH. Fat tissue: an underappreciated source of stem cells for biotechnology. *Trends Biotechnol*. 2006;24(4):150-4.
14. Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N, Grunwald F, Aicher A, Urbich C, Martin H and others. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). *Circulation*. 2002;106(24):3009-17.
15. Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, Fichtner S, Korte T, Hornig B, Messinger D and others.

Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. *Lancet*. 2004;364(9429):141-8.

16. Strauer BE, Brehm M, Zeus T, Kostering M, Hernandez A, Sorg RV, Kogler G, Wernet P. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. *Circulation*. 2002;106(15):1913-8.

17. Fernandez-Aviles F, San Roman JA, Garcia-Frade J, Fernandez ME, Penarrubia MJ, de la Fuente L, Gomez-Bueno M, Cantalapiedra A, Fernandez J, Gutierrez O and others. Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction. *Circ Res*. 2004;95(7):742-8.

18. Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, Zhang JJ, Chunhua RZ, Liao LM, Lin S, Sun JP. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. *Am J Cardiol*. 2004;94:92-95.

19. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, Dzau VJ. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. *Nat Med*. 2003;9(9):1195-201.

20. Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, Sano M, Takahashi T, Hori S, Abe H and others. Cardiomyocytes can be generated from marrow stromal cells *in vitro*. *J Clin Invest*. 1999;103(5):697-705.

21. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. *Circulation*. 2002;105(1):93-8.

22. Banfi A, Podesta M, Fazzuoli L, Sertoli MR, Venturini M, Santini G, Cancedda R, Quarto R. High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: a mechanism for post-bone marrow transplantation osteopenia. *Cancer*. 2001;92(9):2419-28.

23. Banfi A, Bianchi G, Galotto M, Cancedda R, Quarto R. Bone marrow stromal damage after chemo/radiotherapy: occurrence, consequences and possibilities of treatment. *Leuk Lymphoma*. 2001;42(5):863-70.

24. Gluckman E, Horowitz MM, Champlin RE, Hows JM, Bacigalupo A, Biggs JC, Camitta BM, Gale RP, Gordon-Smith EC, Marmont AM and others. Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. *Blood*. 1992;79(1):269-75.

25. Bacigalupo A, Tong J, Podesta M, Piaggio G, Figari O, Colombo P, Sogno G, Tedone E, Moro F, Van Lint MT and others. Bone marrow harvest for marrow transplantation: effect of multiple small (2 ml) or large (20 ml) aspirates. *Bone Marrow Transplant*. 1992;9(6):467-70.

26. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: implications for cell-based therapies. *Tissue Eng*. 2001;7(2):211-28.

27. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P, Hedrick MH. Human adipose tissue is a source of multipotent stem cells. *Mol Biol Cell*. 2002;13(12):4279-95.

28. Ailhaud G, Grimaldi P, Negrel R. Cellular and molecular aspects of adipose tissue development. *Annu Rev Nutr*. 1992;12:207-33.

29. Katz AJ, Tholpady A, Tholpady SS, Shang H, Ogle RC. Cell surface and transcriptional characterization of human adipose-derived adherent stromal (hADAS) cells. *Stem Cells*. 2005;23(3):412-23.

30. Yang L, Zheng J, Hui G. [Research progress of adipose tissue-derived stromal cells]. *Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi*. 2004;18(4):331-4.

31. Zheng B, Cao B, Li G, Huard J. Mouse adipose-derived stem cells undergo multilineage differentiation *in vitro* but primarily osteogenic and chondrogenic differentiation *in vivo*. *Tissue Eng*. 2006;12(7):1891-901.

32. Teplashin AS, Korzhikova SV, Sharifullina SZ, Chupikova NI, Rostovskaia MS, Savchenkova IP. [Characteristics of human mesenchymal stem cells isolated from bone marrow and adipose tissue]. *Tsitologiya*. 2005;47(2):130-5.

33. Rodriguez AM, Pisani D, Dechesne CA, Turc-Carel C, Kurzenne JY, Wdziekonski B, Villageois A, Bagnis C, Breittmayer JP, Groux H and others. Transplantation of a multipotent cell population from human adipose tissue induces dystrophin expression in the immunocompetent mdx mouse. *J Exp Med*. 2005;201(9):1397-405.

34. Rodriguez AM, Elabd C, Amri EZ, Ailhaud G, Dani C. The human adipose tissue is a source of multipotent stem cells. *Biochimie*. 2005;87(1):125-8.

35. De Ugarte DA, Alfonso Z, Zuk PA, Elbarbary A, Zhu M, Ashjian P, Benhaim P, Hedrick MH, Fraser JK. Differential expression of stem cell mobilization-associated molecules on multi-lineage cells from adipose tissue and bone marrow. *Immunol Lett*. 2003;89(2-3):267-70.

36. Wickham MQ, Erickson GR, Gimble JM, Vail TP, Guilak F. Multipotent stromal cells derived from the infrapatellar fat pad of the knee. *Clin Orthop Relat Res*. 2003(412):196-212.

37. Erickson GR, Gimble JM, Franklin DM, Rice HE, Awad H, Guilak F. Chondrogenic potential of adipose tissue-derived stromal cells *in vitro* and *in vivo*. *Biochem Biophys Res Commun*. 2002;290(2):763-9.

38. Safford KM, Safford SD, Gimble JM, Shetty AK, Rice HE. Characterization of neuronal/glial differentiation of murine adipose-derived adult stromal cells. *Exp Neurol*. 2004;187(2):319-28.

39. Gronthos S, Franklin DM, Leddy HA, Robey PG, Storms RW, Gimble JM. Surface protein characterization of human adipose tissue-derived stromal cells. *J Cell Physiol*. 2001;189(1):54-63.

40. Majumdar MK, Thiede MA, Mosca JD, Moorman M, Gerson SL. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. *J Cell Physiol*. 1998;176(1):57-66.

41. Dennis JE, Carbillet JP, Caplan AI, Charbord P. The STRO-1+ marrow cell population is multipotential. *Cells Tissues Organs*. 2002;170(2-3):73-82.

42. Simmons PJ, Gronthos S, Zannettino A, Ohta S, Graves S. Isolation, characterization and functional activity of human marrow stromal progenitors in hemopoiesis. *Prog Clin Biol Res*. 1994;389:271-80.

43. Strem BM, Hicok KC, Zhu M, Wulur I, Alfonso Z, Schreiber RE, Fraser JK, Hedrick MH. Multipotential differentiation of adipose tissue-derived stem cells. *Keio J Med*. 2005;54(3):132-41.

44. Fraser JK, Schreiber R, Strem B, Zhu M, Alfonso Z, Wulur I, Hedrick MH. Plasticity of human adipose stem cells toward endothelial cells and cardiomyocytes. *Nat Clin Pract Cardiovasc Med*. 2006;3 Suppl 1:S33-7.

45. Rehman J, Traktuev D, Li J, Merfeld-Clauss S, Temm-Grove CJ, Bovenkerk JE, Pell CL, Johnstone BH, Considine RV, March KL. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. *Circulation*. 2004;109(10):1292-8.

46. Planat-Benard V, Silvestre JS, Cousin B, Andre M, Nibelink M, Tamarat R, Clergue M, Manneville C, Saillan-Barreau C, Duriez M and oth-

- ers. Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. *Circulation*. 2004;109(5):656-63.
47. Sudhoff T, Sohngen D. Circulating endothelial adhesion molecules (sE-selectin, sVCAM-1 and sICAM-1) during rHuG-CSF-stimulated stem cell mobilization. *J Hematother Stem Cell Res*. 2002;11(1):147-51.
48. Simmons PJ, Masinovsky B, Longenecker BM, Berenson R, Torok-Storb B, Gallatin WM. Vascular cell adhesion molecule-1 expressed by bone marrow stromal cells mediates the binding of hematopoietic progenitor cells. *Blood*. 1992;80(2):388-95.
49. Rehman J, Considine RV, Bovenkerk JE, Li J, Slavens CA, Jones RM, March KL. Obesity is associated with increased levels of circulating hepatocyte growth factor. *J Am Coll Cardiol*. 2003;41(8):1408-13.
50. Von Herrath, M.G., and L.C. Harrison. 2003. Antigen-induced regulatory T cells in autoimmunity. *Nat. Rev. Immunol*. 3:223-232.
51. Puissant B, Barreau C, Bourin P, Clavel C, Corre J, Bousquet C, Taureau C, Cousin B, Abbal M, Laharrague P and others. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. *Br J Haematol*. 2005;129(1):118-29.
52. Lee RH, Kim B, Choi I, Kim H, Choi HS, Suh K, Bae YC, Jung JS. Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue. *Cell Physiol Biochem*. 2004;14(4-6):311-24.
53. Planat-Benard V, Menard C, Andre M, Puceat M, Perez A, Garcia-Verdugo JM, Penicaud L, Casteilla L. Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells. *Circ Res*. 2004;94(2):223-9.
54. Miyahara Y, Nagaya N, Kataoka M, Yanagawa B, Tanaka K, Hao H, Ishino K, Ishida H, Shimizu T, Kangawa K and others. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. *Nat Med*. 2006;12(4):459-65.
55. Muschler GF, Nitto H, Boehm CA, Easley KA. Age- and gender-related changes in the cellularity of human bone marrow and the prevalence of osteoblastic progenitors. *J Orthop Res*. 2001;19(1):117-25.
56. H. Duckers, K. Pinkernell, AM. Milstein, MH Hedrick. The Bedside Celution for isolation of adipose derived regenerative cells. *EJ*. 2006;2:395-398.
57. Rangappa S, Fen C, Lee EH, Bongso A, Sim EK. Transformation of adult mesenchymal stem cells isolated from the fatty tissue into cardiomyocytes. *Ann Thorac Surg*. 2003;75(3):775-9.
58. Gaustad KG, Boquest AC, Anderson BE, Gerdes AM, Collas P. Differentiation of human adipose tissue stem cells using extracts of rat cardiomyocytes. *Biochem Biophys Res Commun*. 2004;314(2):420-7.
59. Watanabe C (2004) Intracoronary adipose tissue derivedstem cell therapy preserves left ventricular function in a porcine infarct model. Paper presented at Transvascular Cardiovascular Therapeutics Annual Meeting, September 2004, Washington DC, USA.
60. Valina C (2004) Intracoronary transplantation of autologous fat tissue derived mesenchymal stem cells in acute myocardial infarctions in pigs [abstract]. *Eur Heart J*. 25 (Suppl):1995.
61. Strem BM, Zhu M, Alfonso Z, Daniels EJ, Schreiber R, Beygui R, MacLellan WR, Hedrick MH, Fraser JK. Expression of cardiomyocytic markers on adipose tissue-derived cells in a murine model of acute myocardial injury. *Cytotherapy*. 2005;7(3):282-91.
62. Alt E, Scharlau M, Pinkernell K, Amadi C, Reddy K, Matthias N, Daemen K, Fotuhi P. Uncultured, autologous adipose-derived stromal cells - a novel cell source for cardiac repair. *Am J Card*. 2005;96(7) (Suppl. 1):71H.
63. Matthias N, Schwarzer M, Pinkernell K, Fotuhi P, Alt EU. Effect of Stem Cells on Left Ventricular Wall Thickness and Capillary Density in Pigs Following Myocardial Infarction. *JACC*. 2006;47(4):206A.
64. Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pascual I, Peiro C, Rodriguez-Montes JA. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. *Dis Colon Rectum*. 2005;48(7):1416-23.
65. Garcia-Olmo D, Garcia-Arranz M, Garcia LG, Cuellar ES, Blanco IF, Prianes LA, Montes JA, Pinto FL, Marcos DH, Garcia-Sancho L. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn's disease: a new cell-based therapy. *Int J Colorectal Dis*. 2003;18(5):451-4.
66. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L, Hofmann T. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. *Proc Natl Acad Sci USA*. 2002;99:8932-8937.
67. Yoshimura K., Matsumoto D., Aiba E., Yamaoka H. and Nagase C. Lipoinjection with a Disposable Screw-Type Syringe for Soft-Tissue Augmentation 27 Yoshimura, K., Matsumoto, D., and Gonda K. A Clinical Trial of Soft-Tissue Augmentation by Lipoinjection with Adipose-Derived Stromal Cells (ASCs). International Fat Applied Technology Society (IFATS); Third Annual Meeting Sept 10 - 13, 2005, Charlottesville VA, p.9.
68. Makkar RR, Lill M, Chen PS. Stem cell therapy for myocardial repair: is it arrhythmogenic? *J Am Coll Cardiol*. 2003;42(12):2070-2.
69. Fotuhi P, Scharlau M, Matthias N, Pinkernell K, Ferguson B, Alt E, Effects of Intracoronary Adipose Tissue Derived Stem Cell Transplantation on Sudden Cardiac Death and Fibrillation Cycle Length in Pigs with Myocardial Infarction. *Clinical Research in Cardiology*. 2006;95(Suppl 5):P167.